Timothy J. Miller, PhD
President & CEO Abeona Therapeutics, Inc.
Timothy J. Miller, Ph.D. is President and Chief Executive Officer and a Director of Abeona Therapeutics Inc. He has 18 years of business development, scientific research, product development and clinical operations expertise, with a focus on transitioning novel biotherapeutics through pre-clinical phases and into Phase 1 and 2 human clinical trials. Dr. Miller was President & CEO of Red5 Pharmaceuticals from 2013 until 2015 and was CEO-in-Residence at BioEnterprise Inc in 2015. He was Senior Director of Product Development at SironRX Therapeutics from 2010 to 2013. Between 1996 and 2010 Dr. Miller held various positions at several biotech companies focusing on gene therapy and regenerative medicine. Dr. Miller earned his Ph.D. in Pharmacology with a focus on Gene therapy/Cystic Fibrosis from Case Western University. He also holds a B.S. in Biology and M.S. in Molecular Biology from John Carroll University (Cleveland, OH).
He has raised over $100M for therapies in rare diseases, cystic fibrosis, cardiovascular disease, wound healing, and dermal disease to advance these therapies into clinical trials. As a serial entrepreneur, he has managed all aspects of research and development, manufacturing of biologics, and clinical program start-up in both public and private companies, with direct experience engaging Food and Drug Administration (FDA) and NIH advisory agencies on multiple Investigational New Drug (IND) submissions. During his career, he has contributed to multiple patent applications, managed intellectual property, and published research in several internationally recognized journals. He has a passion for supporting patient advocacy and developing potential therapeutics for patients with rare disease, and recently returned from a successful summit climb of Mt. Rainier on a rare disease awareness and fundraising adventure.
End of main page content.